Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Sales Growth Not Dependent On Effexor XR, CEO Essner Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The company plans to file six NDAs over the next 24 months, including the Effexor follow-on drug DVS-233. Wyeth believes the antidepressant market will eventually "start to swing back" since the products are safe and effective "within the confines of their labeling."
Advertisement

Related Content

Wyeth Plans To Launch Lybrel, DVS-233 In 2007 After Resolving Manufacturing Issues
Wyeth Plans To Launch Lybrel, DVS-233 In 2007 After Resolving Manufacturing Issues
Effexor XR Follow-On Desvenlafaxine NDA Submitted
Effexor XR Follow-On Desvenlafaxine NDA Submitted
Wyeth Touts Tygacil As First Global NDA Submission
Wyeth To Challenge U.K. Effexor Restrictions
Effexor Script Growth Will Double Antidepressant Market Rate, Wyeth Predicts
FDA Antidepressant Safety Plan Includes "Black Box," Unit-Of-Use Packaging
FDA Antidepressant Safety Plan Includes "Black Box," Unit-Of-Use Packaging

Topics

Advertisement
UsernamePublicRestriction

Register

PS061040

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel